Predicting progression in fibrosing interstitial lung disease
Official title: Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung Disease
Funded at University of Michigan at Ann Arbor · NIH-11251252 · Data updated 2026-11-12
This project uses blood protein patterns to help predict which people with fibrosing interstitial lung disease will get worse over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $691,282 |
| NIH project number | 5R01HL166290-03 |
| Project ID | NIH-11251252 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with fibrosing interstitial lung disease who can provide blood samples, CT imaging, and follow-up clinical data would be ideal candidates.
✕Less likely to help
People without fibrosing ILD or those unable to provide blood samples or clinical follow‑up are unlikely to benefit from this work.
What this research studies
From your perspective, researchers will analyze blood plasma proteins using advanced proteomics and machine‑learning to create a signature linked to short‑term lung decline and three‑year transplant‑free survival. They will validate promising protein markers in an independent patient cohort drawn from pulmonary fibrosis networks. The work also links blood findings with CT imaging and clinical data to improve prediction across different ILD types. The goal is to turn these findings into reliable biomarkers that could guide earlier treatment decisions for people with fibrosing ILD.
Why it matters
Potential benefit: If successful, this could identify people at high risk of rapid decline so they can get earlier treatment and better care planning.
How similar studies have gone: Earlier, smaller proteomic and machine‑learning efforts (including the team's preliminary signature) showed promise but lacked the accuracy and external validation needed for clinical use.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
Related research
Other NIH-funded projects on the same topics.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.